In Depth 23 Jan 2025
mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeutics
…only got into proteins and antibodies when it was already a $20 billion market,” said Greene, back in 2017. And while Alnylam suffered some setbacks itself, including an earlier candidate…